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Thymic volume predicts long-term immune
reconstitution in HIV-infected children treated with
highly active antiretroviral therapy
Mario Clericia, Marina Saresellac, Daria Trabattonia,
Pasquale Ferrantec, Angelo Vanzullid and Alessandra
Viganob
Highly active antiretroviral therapy (HAART)
suppresses viral replication and augments CD4 T
cell counts. HAART-associated immune restora-
tion is often difficult to predict. We verified
whether increases in CD4 cells, and particularly
in cells of the naive phenotype, would be asso-
ciated in HAART-treated children with thymic
volume. Long-term immune reconstitution is
significantly better in children with bigger thy-
muses at the initiation of HAART. Thymic
volume has a strong predictive value for the
immunological effect of HAART.
Highly active antiretroviral therapy (HAART) sup-
presses viral replication and augments CD4 T cells in
HIV-infected individuals. The virological effect of
HAART is highly reproducible; in contrast, the
degree of immune restoration is variable among differ-
ent patients and is difficult to predict [1,2]. CD4 T
cells include both memory (CD4+CD45RO+) and
naive (CD4+CD45RA+CD62L+) subpopulations. In
HAART-treated adults, increases in CD4 T cells are
for a long period of time supported by the redistribu-
tion of memory lymphocytes, whereas early increases
in naive lymphocytes are seen in paediatric patients
[2,3]. Because thymic maturation and selection lead to
the generation of naive T cells, we verified whether
the degree of HAART-associated immune reconstitu-
tion was associated with thymic volume. We report
here that immune reconstitution after 3 years of
therapy is significantly better in children with bigger
thymuses at the initiation of HAART. Thymic vo-
lume thus has a strong predictive value for the
immunological effect of HAART.
Thymus evaluation was performed using magnetic
resonance imaging in 20 HIV vertically infected chil-
dren. Using this technology, thymic tissue appears
sharply hypointense in comparison with mediastinal fat,
and is easily distinguishable from vessels. Sagittal and
axial slices (5 mm) were performed with a 1.5 T
magnet with fast spin echo and T1 and T2 weighted
acquisitions. Thymic dimensions were calculated
according to the formula: 3.14/6 3 D1 3 D2 3 D3
using the transverse diameter of the gland (D1) on the
axial images and the antero-posterior (D2) and cranio-
caudal (D3) diameters obtained from sagittal sections.
The median thymic volume at baseline was 10.39 cm3;
this value was used to divide children into those with a
thymus bigger or smaller than the median. The mean
age (10.6 versus 9.8 years) was comparable between the
two groups of patients, who all had moderate-to-
advanced disease according to the 1994 revised Centers
for Disease Control and Prevention HIV classification.
Children had previously been treated with zidovudine
alone (eight patients) or in association with didanosine
(12 patients), and were subsequently switched to
HAART [lamivudine (4 mg/kg per 12 h) plus stavu-
dine (1 mg/kg per 12 h) plus indinavir (500 mg/m2 per
8 h)]. At baseline, HIV plasma viraemia (21 570 versus
18 758 copies/ml) was comparable in children with
thymic volumes above or below the median. Absolute
CD4 cell counts and the percentage of naive CD4 T
lymphocytes were moderately higher in children with
bigger thymuses (Fig. 1), whereas the percentage of
CD4 T cells was similar between the two groups of
patients.
Immunological and virological parameters were re-
evaluated after 36 months of therapy. HAART was
associated with a dramatic reduction in plasma vir-
aemia in both groups of children (plasma viraemia
, 80 RNA copies/ml in 19/20 individuals), whereas
the effect of antiviral therapy on immune parameters
was more conspicuous in children with thymic
volumes above the median at baseline. HAART-
associated increases in both CD4 cell counts and
CD4 cell percentages were significantly more impress-
ive in these children (Fig. 1a and c) compared with
those with smaller thymuses at baseline (Fig. 1b and
d). As a consequence, the median CD4 : CD8 cell
ratio increased from 0.48 to 1.19 (p , 0.0001) in
children with bigger thymuses and only from 0.34 to
0.57 (not significant) in children with smaller thy-
muses. Naive CD4 T lymphocytes drastically in-
creased in children with bigger thymuses (Fig. 1e),
and were only marginally modified in patients with
smaller thymuses (Fig. 1f). Finally, HAART resulted
in an augmentation of the thymus, which, again, was
more evident when children with bigger thymuses
(median 12.41 versus 21.81 cm3; P ¼ 0.0005) were
compared with those with thymuses below the
median at baseline (median 8.21 versus 10.73 cm3;
P ¼ 0.03).
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HAART-associated suppression of HIV replication is
very similar in different patients. In contrast, the degree
of HAART-associated immune reconstitution is vari-
able among individuals. No established marker predicts
the degree of immune reconstitution in HAART-
treated patients. In particular, immune reconstitution in
children is independent of age and pre-therapy immune
status [1], and has been suggested, but not proved, to
be correlated with thymic function [4–6]. We studied
the immunovirological effect of HAART in 20 HIV-
infected children of similar age and comparable vir-
aemia who underwent the same therapeutic regimen,
and observed that, as expected, although HAART
resulted in the suppression of virus replication in all
children but one, increases in CD4 cell counts were
highly variable. We report here that the size of thymus
at baseline predicts the degree of long-term immune
reconstitution of HAART, independent of the virolo-
gical effects of therapy. This observation is novel, and
expands on a previous report in adults [7], which
suggested that thymus volume, measured after 48
weeks of therapy, could be associated with a larger
increase in the pool of circulating CD4 T cells. Naive
T cells are thymic efferent. In adults, in whom
physiological thymic regression has taken place, these
cells could be generated in thymic residues, in extra-
thymic compartments, or can stem from CD45RO
cells of the CD45RA phenotype [3]. Our data confirm
that, similar to what has been shown after intensive
chemotherapy or bone marrow transplant [8], the
thymic pathway is of pivotal importance in the re-
population of peripheral blood with T lymphocytes in
HIV-infected children undergoing HAART. More
aggressive antiviral regimens or the use of immune
modulators might be considered in patients with
smaller thymuses.
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Fig. 1. CD4 cell absolute numbers (a,b), CD4 cell percen-
tages (c,d), and percentages of CD4+RA+62L+ (naive) lym-
phocytes (e,f) in 20 HIV-infected children studied before the
beginning of highly active antiretroviral therapy (baseline)
and after 36 months of therapy. Panels a, c and e show
values observed in children whose thymic volume deter-
mined by magnetic resonance imaging at baseline was above
the median value of the group; panels b, d and f show values
observed in children whose thymic volume was below the
median value. Each symbol represents a different child.
Mean values and statistical differences are shown.
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The boosting of didanosine by allopurinol permits a
halving of the didanosine dosage
Johan R. Boelaerta, Genevie`ve M. Domb, Alwin D.R.
Huitemac, Jos H. Beijnenc and Joep M.A. Langed
The pharmacokinetic boosting of didanosine by
allopurinol was studied in four HIV-1-positive
patients taking didanosine, hydroxyurea and
chloroquine, in whom the didanosine dosage was
halved and allopurinol was added at 300 mg/day.
Didanosine plasma levels and HIV-1-RNA levels
remained unchanged after 4 and 17–20 months,
respectively. Halving the didanosine dosage with
allopurinol reduces treatment costs, and may lend
itself to once-daily combination therapies, which
are of particular interest for HIV therapy in
resource-poor countries.
Pharmacokinetic interactions are important in antire-
troviral therapy and are sometimes deliberately used to
potentiate anti-HIV-1 drugs. For instance, several
protease inhibitors are boosted by ritonavir, because of
the inhibition of selected P450 isoenzymes by ritonavir,
which represent the major elimination pathway of these
drugs. Nucleoside reverse transcriptase inhibitors (NR
TI) are not eliminated by the P450 system and, in
general, are less prone to pharmacokinetic interactions
than protease inhibitors and non-nucleoside reverse
transcriptase inhibitors. The potentiation of NRTI, and
in particular of didanosine by hydroxyurea, is not
caused by a pharmacokinetic interaction but the cellular
effects of hydroxyurea that favour the NRTI-induced
inhibition of reverse transcriptase [1].
We wish to draw attention to the potential usefulness
of the pharmacokinetic interaction between didanosine
and allopurinol. This xanthine-oxidase inhibitor, used
for decades to inhibit uric acid synthesis, increases the
plasma levels of didanosine in both rats and humans,
suggesting that the purine nucleoside didanosine under-
goes an important first-pass effect mediated by
xanthine-oxidase, an enzyme present in both the
intestinal wall and the liver [2]. In two oral single-dose
studies in 14 healthy human volunteers and seven
HIV-infected individuals, respectively, pretreatment
with 300 mg allopurinol a day for 7 days doubled the
peak plasma levels (Cmax) and the total area-under-the-
plasma-concentration-time curves of didanosine, with-
out affecting its terminal half-life [2,3]. This enhanced
oral systemic bioavailability of didanosine by the con-
comitant administration of allopurinol led us to hy-
pothesize that co-treatment with allopurinol may allow
the dosage of didanosine to be halved in HIV-1-
infected patients.
We investigated this hypothesis in four treatment-naive
patients (three men and one woman, two Caucasians
and two black individuals, aged 29–42 years) who had
initiated therapy with didanosine, hydroxyurea and
chloroquine. This anti-HIV-1 drug combination is
based on the enhancement of the antiretroviral effect of
didanosine by hydroxyurea [1], and on the additive
antiviral effect of chloroquine, observed in vitro [4,5].
In the four patients studied, the combination of
didanosine (four chewable tablets of 100 mg a day),
hydroxyurea (500 mg twice a day) and chloroquine
(100 mg a day) had resulted in a good virological
response, with HIV-1-RNA plasma levels of less than
400 copies/ml (Amplicor; Roche Diagnostic Systems,
Inc., Branchburg, NJ, USA) at 4–20 months (Table 1,
column 4). The patients volunteered to participate in
the trial, approved by the Institutional Ethical Commit-
tee, which consisted of switching their current therapy
to a half-dose didanosine scheme, supplemented with
allopurinol: didanosine two chewable tablets of 100 mg
a day, taken on an empty stomach, together with
allopurinol 300 mg a day, chloroquine base 100 mg a
day and hydroxyurea 500 mg twice a day. In a further
effort to simplify therapy and improve adherence, the
patients were asked at between 4 and 8 months after
the switch to take all medication daily (including
hydroxyurea) on an empty stomach. The plasma levels
of didanosine at 0.75 (C0:75) and 4 (C4) hours after
intake were assayed by high-performance liquid chro-
matography [6] on three occasions: before the switch
(didanosine dose 400 mg a day), as well as 1 and (in
two patients) 4 months after the switch (didanosine
dose 200 mg a day plus allopurinol). Plasma HIV-1-
RNA levels and CD4 cell counts were monitored
before this switch and in the subsequent months, with
a post-switch follow-up ranging between 17 and 20
months.
As hypothesized and as shown in Table 1, the addition
of allopurinol to the halved dose of didanosine did not
result in significant changes in didanosine plasma levels,
as measured by C0:75, C4 or area-under-the-concentra-
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tion-time curve (p . 0.5) at 1 month or 4 months after
the switch. The switch did not cause a significant
change in the plasma HIV-1-RNA levels, which
remained suppressed at less than 400 copies/ml in all
patients. The course of the CD4 cell count was
variable, as expected with the use of hydroxyurea [1].
The therapy switch did not result in any adverse effect.
Although this pilot study was performed on a limited
number of patients, it confirms the hypothesis that
allopurinol boosts didanosine plasma levels, which
allows the use of a half dose of didanosine. Further-
more, it indicates that this boosting persists after several
months of concomitant treatment.
The observed boosting of didanosine by allopurinol
may have implications for the choice of antiretroviral
therapy in resource-poor countries, where both the
cost of drugs and the simplicity of drug regimens are of
major importance. First, allopurinol, an inexpensive
generic compound, may allow the dosage and hence
the cost of didanosine to be halved. Second, half-
didanosine plus allopurinol may lend itself to combina-
tion therapy with other drugs in a once daily regimen,
to be used or not in directly observed therapy. In the
present study, half-didanosine plus allopurinol was
combined with hydroxyurea and chloroquine daily. As
concerns have arisen about the long-term safety of
hydroxyurea [7,8], other compounds may be combined
with half-dose didanosine plus allopurinol in a daily
regimen, such as (among others) lamivudine and one of
the non-nucleoside reverse transcriptase inhibitor drugs
nevirapine or efavirenz, with or without chloroquine
[4]. However, the potential toxicity of allopurinol is
well known and should be taken into account [9]. It is
not known whether HIV-1 infection may affect the
incidence of hypersensitivity reactions to this drug. The
drug’s tolerance may be tested by the administration of
allopurinol as a single compound before its use in
combination therapy. Clinical trials are required to
study the long-term efficacy, tolerance and applicability
of these new combinations in resource-poor settings.
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Table 1. Results of co-administration of allopurinol and halving the dose of didanosine.
Patient no.
At start of
therapy
Before
switching
After
switching
1 HIV-1 RNA (copies/ml) 11 400 , 50 163
CD4 cell count (cells/l) 400 (23%) 410 (29%) 560 (24%)
Plasma didanosine (ng/ml) (45/240 min) 1186/77 1031/99a
835/102b
Plasma didanosine AUC (h3 mg/l) 2044 1984a
1772b
2 HIV-1 RNA (copies/ml) 31 100 66 50
CD4 cell count (cells/l) 680 (31%) 640 (37%) 350 (20%)
Plasma didanosine (ng/ml) (45/240 min) 1445/91 1575/85a
2032/102b
Plasma didanosine AUC (h3 mg/l) 2420 2539a
3161b
3 HIV-1 RNA (copies/ml) 11 990 , 50 , 50
CD4 cell count (cells/l) 360 (11%) 280 (17%) 230 (12%)
Plasma didanosine (ng/ml) (45/240 min) 2044/64 2480/90a
Plasma didanosine AUC (h3 mg/l) 2969 3616a
4 HIV-1 RNA (copies/ml) 118 000 192 391
CD4 cell count (cells/l) 210 (11%) 170 (12%) 210 (10%)
Plasma didanosine (ng/ml) (45/240 min) 2759/115 1435/150a
Plasma didanosine AUC (h3 mg/l) 4075 2731a
AUC, Area-under-the-concentration-time curve.
a1 month after the switch.
b4 months after the switch.
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Utility of patch testing in patients with
hypersensitivity syndromes associated with
abacavir
Elizabeth J. Phillipsa,b,c, John R. Sullivand, Sandra R.
Knowlesa,c and Neil H. Shearc
A diagnostic test would be useful to help elimi-
nate the associated morbidity and mortality after
full-dose rechallenge with abacavir in patients
with suspected hypersensitivity. We describe se-
ven patients with syndromes compatible with
abacavir hypersensitivity who had positive patch
tests. Immunohistochemistry on skin biopsies
from the acute prospectively identified patients
with rash (n 3) matched those from positive-
patch patients (n 7), suggesting an identical
pathophysiological process. No patients devel-
oped systemic symptoms or signs during patch
testing.
Abacavir is a nucleoside analogue used in combination
with other antiretroviral drugs for the treatment of
HIV. Approximately 2–5% of patients starting abacavir
will experience a hypersensitivity syndrome, most
commonly characterized by combinations of fever,
rash, malaise, nausea, vomiting and diarrhoea. Severe
reactions such as shock and even death have been
described with full dose rechallenge after the occur-
rence of the hypersensitivity syndrome [1].
Patch testing is an ‘in-vivo’ test that involves the
application of dilute, non-irritating concentrations of
the substance or drug in a vehicle such as petrolatum to
the surface of the skin. There is significant experience
with patch testing for the diagnosis of T cell-mediated
processes such as allergic contact dermatitis. Patch
testing is simple and inexpensive to perform. Currently
there is limited information as to the use of patch
testing for other potentially cell-mediated processes
such as drug reactions [2]. The rationale for use in
these reactions is supported by the potential metabolism
of the parent drug to reactive metabolite in skin and
the presence of resident CD8 cells from skin biopsies of
patients with acute drug-induced hypersensitivity syn-
dromes [3].
We describe seven patients who developed positive
patch tests to abacavir within 4 months of a presumed
abacavir hypersensitivity reaction (Table 1, Fig. 1).
One patient (case 6) was identified 33 months after the
initial reaction. Four patients were identified prospec-
tively at the time of the reaction, and three were
identified retrospectively after the initial reaction. All
patients met a minimum case definition of probable
abacavir hypersensitivity syndrome, defined as either
having at least two intensifying symptoms of rash,
fever, gastrointestinal complaints, headache and resolu-
tion within 24 h of stopping the drug without an
alternative explanation or a positive rechallenge to
abacavir. Rash occurred in three out of four prospec-
tively identified patients as part of the acute reaction,
with immunohistochemistry documented (Table 1).
Patients and HIV-negative controls had one patch
panel of 1% abacavir and 10% abacavir in a petrolatum
base applied to the mid-back. All patches were taken
off at 48 h. Reading took place at 48 and 96 h in cases
1 to 3. Cases 4 to 7 and four additional HIV-infected
controls tolerating or known to have tolerated abacavir
also had 0.1, 5, 15 and 25% abacavir added to the patch
panel, with additional readings at 1, 24, 48 and 96 h.
Two HIV-negative controls with no previous abacavir
exposure and five HIV-positive controls with previous
abacavir exposure matched for age, sex, race, CD4 cell
count and viral load had negative patch tests at 48 and
96 h.
Patch testing was positive in seven patients with
probable abacavir hypersensitivity and negative in seven
controls. This may be an extremely useful diagnostic
modality for identifying patients with true abacavir
reactions. HIV patients are often started on multiple
concurrent medications, making the implication of a
single drug in a reaction difficult. The clinical diagnosis
of abacavir hypersensitivity syndrome was further
strengthened in our six out of seven patch test-positive
patients by subsequent rechallenge and tolerance of of
of other antiretroviral drugs that they were taking at
the time of the initial reaction. The pathological
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Table 1. Clinical summary of patch test-positive patients.
Case Age/sex Details of abacavir reaction Concurrent drugs Skin biopsy Patch test Patch test biopsy Follow-up
1 32/M Fever, myalgia and malaise 8 days
after starting abacavir
d4T, 3TC, efavirenz,
nelﬁnavir
N/A Performed 4 months after acute
reaction. Positive at all
concentrations at 48 and 96 h
Lymphocytic vasculitis, CD4,
CD8, HLA-DR, CD30-
negative
Tolerating d4T, 3TC, nelﬁnavir,
efavirenz
2 62/M Fever, headache, malaise, nausea
9 days after starting abacavir,
day 11 developed rash and
hypotension
d4T, efavirenz Lymphocytic
vasculitis. CD4, CD8,
HLA-DR, CD30-
negative
3 months after acute reaction.
Positive at all concentrations at 48
and
96 h
Lymphocytic vasculitis. CD4,
CD8, HLA-DR, CD30-
negative
Tolerating d4T, 3TC, efavirenz
3 50/M Fever, nausea, diarrhea, myalgias
5 days after starting abacavir.
Day 7 developed generalized rash,
cervical adenopathy and
hypotension during an
observed dose
d4T, 3TC efavirenz Lymphocytic
vasculitis. CD4, CD8,
HLA-DR, CD30-
negative
2 months after acute reaction.
Intense blistering reaction worse
at 10% localized to patch test
at 48 and 96 h
Lymphocytic vasculitis. CD4,
CD8, HLA-DR+, CD30-
negative
Tolerating d4T, 3TC, efavirenz,
lopinavir/ritonavir
4 43/M Fever, rash, anorexia and malaise
2.5 weeks after starting abacavir
ddI, nevirapine,
amprenavir, lopinavir/
ritonavir
N/A 2 months after acute reaction.
Negative
patch test at 1 h. Positive patch
test at 24, 48 and 96 h
(all concentrations)
Lymphocytic vasculitis. CD4,
CD8, HLA-DR+, CD30-
negative, CD23-positive
Tolerating amprenavir
lopinavir/ritonavir, efavirenz,
d4T, 3TC
5 47/M Fever, nausea, skin rash 6 days
after starting abacavir
ddI, amprenavir,
delavirdine, combivir
N/A 2 months after acute reaction.
Negative patch test at 1 h. Positive
patch test at 24, 48 and 96 h
(all concentrations)
Lymphocytic vasculitis. CD4,
CD8, HLA-DR, CD30-
negative
Tolerated rechallenge with
tenofovir, ddI, amprenavir,
delavirdine, Combivir (ZDV/
3TC)
6 43/M Fever, skin rash, myalgias 7 days
after starting abacavir, which
intensiﬁed
Abacavir, efavirenz,
d4T, 3TC
N/A 33 months after acute reaction.
Negative patch test at 1 h. Positive
patch test at 24, 48 and 96 h
(all concentrations)
Refused biopsy On drug holiday
7 48/M Fever, malaise, headache day 8,
intensiﬁcation and rash day 9,10
Abacavir, 3TC,
efavirenz
Lymphocytic
vasculitis, CD4, CD8,
HLA-DR, CD30-
negative
6 weeks after acute reaction.
Negative patch test at 1 h. Positive
patch test at 24, 48 and 96 h
(all concentrations)
Lymphocytic vasculitis. CD4,
CD8, HLA-DR, CD30-negative
Tolerating Combivir (ZDV/3TC),
efavirenz
ddI, Didanosine; d4T, stavudine; 3TC, lamivudine; ZDV, zidovudine.
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concordance between the two biopsies and patch test-
ing further strengthens this, and sheds light on the
pathophysiology of the acute skin reaction and positive
patch tests. The immunohistochemistry on the acute
skin rash biopsies and patch biopsies are in fact identical
to previously presented data on skin biopsies from
patients with acute abacavir hypersensitivity syndrome
[4]. The absence of B cell markers and the presence of
HLA-DR in all of the biopsies suggests a primarily
cell-mediated, T helper cell type 1 response.
These preliminary results suggest that an inexpensive
and safe procedure such as patch testing may be a useful
adjunct to the clinical diagnosis of abacavir hypersensi-
tivity syndrome. Cases 4 to 7 illustrates that patch
testing can become positive within 24 h of applying the
patch. It should be emphasized that this test is currently
a research tool, and a negative patch test at this time
cannot be interpreted as grounds for full-dose unsuper-
vised rechallenge with abacavir. Case 6 illustrates that
patch tests can be positive remote from the initial
exposure. However, the exact time course of when the
test becomes positive in relation to the hypersensitivity
syndrome and the expected duration of positivity in
these patients is currently unknown and is the subject
of further investigation.
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Bilateral carotid stenosis in a young female HIV
patient treated with highly active antiretroviral
therapy
Simona Landonioa, Tiziana Quirinoa, Angelo Pelucchib,
Carlo Magnia, Massimo Coena, Tiziano Porrettab, Ivano
Faggiona, Paolo Bonfantia and Gian Marco Vigevania
In the past few years, some cases of vascular
pathology in HIV-positive patients treated with
highly active antiretroviral therapy (HAART)
have been reported. We describe a case of severe
and premature vascular disease, occurring in a
young female patient, multiexperienced for
HAART, who is part of a cohort of patients
followed for drug-induced toxicity. After 6 years
of treatment she suffered a bilateral carotid ste-
nosis; the only risk factors were cigarette smok-
ing and hypercholesterolemia.
Among the long-term toxicity effects of antiretroviral
therapy, lipid metabolism disorders and an increased
risk of atherosclerosis constitute a problem of great
interest [1,2]. Cases of premature vascular pathology in
patients treated with highly active antiretroviral therapy
(HAART) are reported with increasing frequency in
the literature, even though the actual incidence of this
phenomenon is still under study [3,4]. We describe a
case of bilateral carotid stenosis in a young female
patient. She is part of a cohort of 1480 patients treated
with HAART, under observation since 1997 to assess
the incidence of adverse reactions [5].
Fig. 1. Patch testing at 24 h illustrating dose reponse (case
5).
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Clinical case
An HIV-positive 37-year-old woman, known for
heterosexual risk since 1987, was started on antiretro-
viral therapy with nucleoside reverse transcriptase in-
hibitors in 1993. Since 1998 the therapy was enhanced
first with non-nucleoside reverse transcriptase inhibitors
and then with protease inhibitors. In June 1999, as a
result of unsatisfactory immunovirological control, a
mega-HAART regimen with stavudine, abacavir, lami-
vudine, ritonavir and indinavir was introduced.
In July of the same year, the patient suffered occasional
paresthesia in her fingers, each episode lasting only a
few minutes. The symptoms got increasingly worse up
to November 1999, when she showed weakness and
reduced sensitivity in her left arm. The patient was
hospitalized and a nuclear magnetic resonance imaging
showed signal alteration in the right occipito-parietal
region, which was not modified after contrast injection
and was compatible with an ischaemic stroke. Tests for
thrombophilic conditions: prothrombin time, platelet
count, lupus anticoagulant, silica clotting time, factor
pathway inhibitors to coagulation (C and S proteins)
and antinuclear antibodies were negative. Doppler
sonography showed soft plaque with less than 20%
stenosis at the origin of the right internal carotid artery.
The patient was introduced to antiplatelet therapy,
resulting in a gradual remission of her neurological
symptoms.
In June 2000, the patient suffered new episodes of
paresthesia of the left hand as well as amaurosis fugax
in the left eye. A brain computed tomography scan
showed an ischaemic lesion in the right occipito-
parietal region. The Doppler sonography led us to
suspect severe stenosis in the right common carotid
artery. A computed tomography angiography con-
firmed a total obstruction of the right carotid artery,
as well as the presence of soft lipidic plaque causing
stenosis of the left carotid bifurcation. The patient
first underwent endarterectomy of the left carotid
bifurcation (Fig. 1), later followed by a right sub-
clavian-carotid by-pass. The patient currently remains
symptom-free; she is proceeding with antiretroviral
and antiplatelet therapy. The Doppler sonography
shows normal blood flow in the carotid territory,
bilaterally.
An analysis of cardiovascular risk factors showed that,
from the early neurological symptoms, the patient’s
cholesterol levels were slightly high (maximum count:
275 mg/dl); her triglyceride levels were always normal.
She never showed any hypertension and she has never
taken oral contraceptives. She smokes approximately 20
cigarettes per day. There is no history of cardiovascular
disease in her family.
Conclusion
Bilateral carotid vascular disease in young women is a
decidedly rare event in the general population. Such an
event is generally correlated to major concomitant risk
factors [6,7]. In this case, the only risk factors linked to
cardiovascular disease are that the patient smokes and
that her cholesterol was slightly too high. We must
therefore consider the possibility that antiretroviral
treatment may have contributed to the occurrence of
vascular pathology.
Should such clinical data be further confirmed, period-
ical adverse event monitoring schemes for HIV-positive
patients undergoing HAART therapy will probably
need to be reassessed.
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